Alterity Secures FDA Alignment, Reports A$44.5M Cash and 41% MSA Treatment Effect
Alterity ended Q3 FY26 with A$44.53M cash and secured FDA alignment on key ATH434 Phase 3 elements ahead of its mid-2026 End-of-Phase 2 meeting. Phase 2 data showed ATH434 slowed MSA progression by 41% (−4.0 points at 50mg, p=0.034) in MuSyCA assessment.
1. Q3 FY26 Financial Position
At 31 March 2026, Alterity reported a cash balance of A$44.53 million, providing runway for its ATH434 development program and upcoming regulatory and clinical activities.
2. Regulatory Progress for ATH434
Alterity engaged FDA in two Type C meetings, securing written feedback on clinical pharmacology, non-clinical development and CMC requirements. The company remains on track for an End-of-Phase 2 meeting in mid-2026 to finalize the design of its pivotal Phase 3 trial in Multiple System Atrophy.
3. Phase 2 Efficacy Data and Leadership Appointments
New analyses from the ATH434-201 Phase 2 trial demonstrated a 41% slowing of MSA progression (−4.0 MuSyCA points at 50 mg, p=0.034) at Week 52. Alterity strengthened its leadership with Dr. Daniel Claassen as Chief Medical Advisor and Ann Cunningham joining the board to bolster clinical and commercial expertise.